ST. LOUIS & MONTREAL--(BUSINESS WIRE)--June 28, 2006--Tripos, Inc. (Nasdaq:TRPS - News), a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos Discovery Research, Ltd. (TDR), based in Bude, England, has secured an undisclosed milestone payment from Chronogen Inc. as a result of a small-molecule drug discovery collaboration progressing into pre-clinical development. Chronogen is a drug discovery company developing therapeutics to treat highly prevalent age-dependent diseases.
